Merck adds an overall survival benefit while Bristol sinks further.

The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.

A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.

The first-line liver cancer Emerald-1 trial is positive, but only up to a point.

Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.

Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.